205 related articles for article (PubMed ID: 31324389)
1. Quantitative proteomics analysis of differentially expressed proteins in activated B-cell-like diffuse large B-cell lymphoma using quantitative proteomics.
Gao HX; Nuerlan A; Abulajiang G; Cui WL; Xue J; Sang W; Li SJ; Niu J; Ma ZP; Zhang W; Li XX
Pathol Res Pract; 2019 Sep; 215(9):152528. PubMed ID: 31324389
[TBL] [Abstract][Full Text] [Related]
2. A super-SILAC based proteomics analysis of diffuse large B-cell lymphoma-NOS patient samples to identify new proteins that discriminate GCB and non-GCB lymphomas.
van der Meeren LE; Kluiver J; Rutgers B; Alsagoor Y; Kluin PM; van den Berg A; Visser L
PLoS One; 2019; 14(10):e0223260. PubMed ID: 31603917
[TBL] [Abstract][Full Text] [Related]
3. Identification of potential drugs for diffuse large b-cell lymphoma based on bioinformatics and Connectivity Map database.
Luo B; Gu YY; Wang XD; Chen G; Peng ZG
Pathol Res Pract; 2018 Nov; 214(11):1854-1867. PubMed ID: 30244948
[TBL] [Abstract][Full Text] [Related]
4. Screening and identification of differentially expressed microRNAs in diffuse large B-cell lymphoma based on microRNA microarray.
Gao HX; Li SJ; Wang MB; Yan SF; Cui WL; Ma ZP; Xue J; Sang W; Zhang W; Li XX
Oncol Lett; 2021 Nov; 22(5):753. PubMed ID: 34539857
[TBL] [Abstract][Full Text] [Related]
5. FOXP2-positive diffuse large B-cell lymphomas exhibit a poor response to R-CHOP therapy and distinct biological signatures.
Wong KK; Gascoyne DM; Soilleux EJ; Lyne L; Spearman H; Roncador G; Pedersen LM; Møller MB; Green TM; Banham AH
Oncotarget; 2016 Aug; 7(33):52940-52956. PubMed ID: 27224915
[TBL] [Abstract][Full Text] [Related]
6. Identification of key microRNAs associated with diffuse large B-cell lymphoma by analyzing serum microRNA expressions.
Meng Y; Quan L; Liu A
Gene; 2018 Feb; 642():205-211. PubMed ID: 29128636
[TBL] [Abstract][Full Text] [Related]
7. Discovery and validation of immune-associated long non-coding RNA biomarkers associated with clinically molecular subtype and prognosis in diffuse large B cell lymphoma.
Zhou M; Zhao H; Xu W; Bao S; Cheng L; Sun J
Mol Cancer; 2017 Jan; 16(1):16. PubMed ID: 28103885
[TBL] [Abstract][Full Text] [Related]
8. TCL1 as a hub protein associated with the PI3K/AKT signaling pathway in diffuse large B-cell lymphoma based on proteomics methods.
Gao HX; Li SJ; Niu J; Ma ZP; Nuerlan A; Xue J; Wang MB; Cui WL; Abulajiang G; Sang W; Zhang W; Li XX
Pathol Res Pract; 2020 Feb; 216(2):152799. PubMed ID: 31932115
[TBL] [Abstract][Full Text] [Related]
9. TRPM4 expression is associated with activated B cell subtype and poor survival in diffuse large B cell lymphoma.
Loo SK; Ch'ng ES; Md Salleh MS; Banham AH; Pedersen LM; Møller MB; Green TM; Wong KK
Histopathology; 2017 Jul; 71(1):98-111. PubMed ID: 28248435
[TBL] [Abstract][Full Text] [Related]
10. Gene expression profiling of diffuse large B-Cell lymphomas supervised by CD5 expression.
Miyazaki K; Yamaguchi M; Imai H; Kobayashi K; Tamaru S; Kobayashi T; Shiku H; Katayama N
Int J Hematol; 2015 Aug; 102(2):188-94. PubMed ID: 26009281
[TBL] [Abstract][Full Text] [Related]
11. Super-SILAC allows classification of diffuse large B-cell lymphoma subtypes by their protein expression profiles.
Deeb SJ; D'Souza RC; Cox J; Schmidt-Supprian M; Mann M
Mol Cell Proteomics; 2012 May; 11(5):77-89. PubMed ID: 22442255
[TBL] [Abstract][Full Text] [Related]
12. Proteomic Landscape of Extracellular Vesicles for Diffuse Large B-Cell Lymphoma Subtyping.
Carvalho AS; Baeta H; Henriques AFA; Ejtehadifar M; Tranfield EM; Sousa AL; Farinho A; Silva BC; Cabeçadas J; Gameiro P; Silva MGD; Beck HC; Matthiesen R
Int J Mol Sci; 2021 Oct; 22(20):. PubMed ID: 34681663
[TBL] [Abstract][Full Text] [Related]
13. Clinicopathologic implication of microRNA-197 in diffuse large B cell lymphoma.
Yang JM; Jang JY; Jeon YK; Paik JH
J Transl Med; 2018 Jun; 16(1):162. PubMed ID: 29890998
[TBL] [Abstract][Full Text] [Related]
14. Diffuse large B-cell lymphoma.
Li S; Young KH; Medeiros LJ
Pathology; 2018 Jan; 50(1):74-87. PubMed ID: 29167021
[TBL] [Abstract][Full Text] [Related]
15. Proteomic-Based Analysis of Hypoxia- and Physioxia-Responsive Proteins and Pathways in Diffuse Large B-Cell Lymphoma.
Duś-Szachniewicz K; Gdesz-Birula K; Zduniak K; Wiśniewski JR
Cells; 2021 Aug; 10(8):. PubMed ID: 34440794
[TBL] [Abstract][Full Text] [Related]
16. Novel drug targets for personalized precision medicine in relapsed/refractory diffuse large B-cell lymphoma: a comprehensive review.
Camicia R; Winkler HC; Hassa PO
Mol Cancer; 2015 Dec; 14():207. PubMed ID: 26654227
[TBL] [Abstract][Full Text] [Related]
17. ABC, GCB, and Double-Hit Diffuse Large B-Cell Lymphoma: Does Subtype Make a Difference in Therapy Selection?
Nowakowski GS; Czuczman MS
Am Soc Clin Oncol Educ Book; 2015; ():e449-57. PubMed ID: 25993209
[TBL] [Abstract][Full Text] [Related]
18. A 9 series microRNA signature differentiates between germinal centre and activated B-cell-like diffuse large B-cell lymphoma cell lines.
Culpin RE; Proctor SJ; Angus B; Crosier S; Anderson JJ; Mainou-Fowler T
Int J Oncol; 2010 Aug; 37(2):367-76. PubMed ID: 20596664
[TBL] [Abstract][Full Text] [Related]
19. Proteomic Profiling of Diffuse Large B-Cell Lymphomas.
Kwiecińska A; Porwit A; Souchelnytskyi N; Kaufeldt A; Larsson C; Bajalica-Lagercrantz S; Souchelnytskyi S
Pathobiology; 2018; 85(4):211-219. PubMed ID: 29617697
[TBL] [Abstract][Full Text] [Related]
20. PDGFD induces ibrutinib resistance of diffuse large B‑cell lymphoma through activation of EGFR.
Jin J; Wang L; Tao Z; Zhang J; Lv F; Cao J; Hu X
Mol Med Rep; 2020 May; 21(5):2209-2219. PubMed ID: 32186759
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]